Acumen Pharmaceuticals Inc (ABOS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Acumen Pharmaceuticals Inc stock (ABOS) is currently trading at $2.59. Acumen Pharmaceuticals Inc PS ratio (Price-to-Sales) is 538.78. Analyst consensus price target for ABOS is $7.20. WallStSmart rates ABOS as Sell.
- ABOS PE ratio analysis and historical PE chart
- ABOS PS ratio (Price-to-Sales) history and trend
- ABOS intrinsic value — DCF, Graham Number, EPV models
- ABOS stock price prediction 2025 2026 2027 2028 2029 2030
- ABOS fair value vs current price
- ABOS insider transactions and insider buying
- Is ABOS undervalued or overvalued?
- Acumen Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ABOS Piotroski F-Score and Altman Z-Score
- ABOS analyst price target and Smart Rating
Acumen Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Acumen Pharmaceuticals Inc (ABOS) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Acumen Pharmaceuticals Inc (ABOS) Key Strengths (2)
74.66% of shares held by major funds and institutions
Trading at 1.74x book value, attractively priced
Supporting Valuation Data
Acumen Pharmaceuticals Inc (ABOS) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 538.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Acumen Pharmaceuticals Inc (ABOS) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.74) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (538.78) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -85.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -85.90% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABOS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABOS's Price-to-Sales ratio of 538.78x trades 136% above its historical average of 228.54x (84th percentile), historically expensive. The current valuation is 32% below its historical high of 787.96x set in Aug 2021, and 1152% above its historical low of 43.03x in May 2025. Over the past 12 months, the PS ratio has expanded from ~50.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Acumen Pharmaceuticals Inc (ABOS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Acumen Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 329,000 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 6677% of revenue (22M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -30M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Acumen Pharmaceuticals Inc.
Bottom Line
Acumen Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(67 last 3 months)
| Insider | Type | Shares |
|---|---|---|
RA, CAPITAL MANAGEMENT, L.P. Director, 10% Owner | Buy | +6,060,606 |
| Insider | Type | Shares |
|---|---|---|
MEISNER, DEREK M Chief Legal Officer & Corp Sec | Sell | -5,633 |
Data sourced from SEC Form 4 filings
Last updated: 8:22:00 AM
About Acumen Pharmaceuticals Inc(ABOS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.